On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Earth Science Tech, Inc. (ETST) Plans to Battle Opioid Addiction with Human Clinical Trials in 2019

  • Centers for Disease Control and Prevention, in March 2018, estimated ‘economic burden’ of opioid misuse at $78.5 billion annually
  • ETST plans to complete white paper, begin human clinical trials by 2019; company intends to investigate drugs that combine mineral element and cannabinoid industrial hemp oil
  • Goal for biotech company is to fight opioid addiction with over-the-counter (OTC) treatment drug and a cannabinoid companion generic drug

Earth Science Tech, Inc. (OTC: ETST) is planning to fight opioid addiction in the near future by completing its white paper and beginning human clinical trials in 2019. The epidemic is projected to claim nearly 500,000 American lives by 2027, according to a study by STAT (http://nnw.fm/9Twid).

The ETST white paper and planned human clinical studies deal with the measure of the efficacy of combination drugs against opioid dependency. The company will investigate the synergies between mineral elements and full spectrum cannabinoid industrial hemp with the goal of developing OTC and generic drugs that treat opioid addiction.

ETST is a biotech company focused on the cannabinoid, pharmaceutical and nutraceutical markets. In addition to drug research, it also performs R&D testing for medical devices. The company holds several subsidiaries, including Earth Science Pharmaceutical, Inc.; Cannabis Therapeutics, Inc.; KannaBidioiD, Inc.; and Canna Inno Laboratories, Inc., based in Montreal, Canada.

The company’s proposed OTC drug would be intended to reduce the cravings of opioid addicts. The other would be a generic designed to reduce the danger of side effects and make the first drug more effective, according to ETST. The purpose of the human trial is to develop a methodology that prevents fatal overdoses and relieves the side effects of withdrawal.

The Centers for Disease Control and Prevention (CDC), in a March 2018 revised report, estimated the ‘economic burden’ of opioid misuse at $78.5 billion annually in the U.S., including in that figure health care, addiction treatment and the involvement of the justice system. The National Institute on Drug Abuse terms it a national health crisis (http://nnw.fm/se3kA).

For more information, visit the company’s website at www.EarthScienceTech.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Archives

Select A Month

Contact us: 212.418.1217